Factors affecting rAAV titers during triple-plasmid transient transfection in HEK-293 cells

Martina Pistek1, Peter Andorfer1, Reingard Grabherr2

  • 1Gene Therapy Process Development, Baxalta Innovations GmbH, a part of Takeda companies, Uferstraße 15, 2304, Orth an der Donau, Austria.

Biotechnology Letters
|September 11, 2024
PubMed

Related Concept Videos